

HTA - - Health Technology Assessment Report

# Embedded Specialist Palliative Care in Cystic Fibrosis: Results of a Randomized Feasibility Clinical Trial.

**Code:** PM36350712

**Year:** 2023 **Date:** 2014

**Author:** Kavalieratos D

## Study design (if review, criteria of inclusion for studies)

Review, HTA report

## List of included studies (3)

TRANSPORT, NCT01807949, VX12-809-104; lumacaftor and ivacaftor vs placebo; phase III. TRAFFIC, NCT01807923, VX12-809-103; lumacaftor and ivacaftor vs placebo; phase III. NCT01931839, VX12-809-105; phase III extension.

## Participants

patients aged 12 years and older with cystic fibrosis (CF) who are homozygous for the F508del-CFTR mutation.

## Interventions

Lumacaftor is a cystic fibrosis transmembrane conductance regulator (CFTR) corrector and ivacaftor is a CFTR potentiator.

## Outcome measures

Primary: Relative change in percent predicted forced expiratory volume in 1 second (FEV1); safety. Secondary: Absolute change in percent predicted FEV1, change in body mass index (BMI), number of pulmonary exacerbations, cystic fibrosis questionnaire (CFQ-R) score, safety.

<http://dx.doi.org/10.1089/jpm.2022.0349>

## See also

J Palliat Med. 2023 Apr;26(4):489-496. doi: 10.1089/jpm.2022.0349. Epub 2022 Nov 9.

## Keywords

Adult; Aged; CFTR Modulators; Genetic Predisposition to Disease; pharmacological\_intervention; placebo; VX-770; VX-809; ivacaftor; Aminophenols; lumacaftor;